MedTrace Logo

Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis

NCT02559869 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 86

Last updated 2020-05-21

No results posted yet for this study

Summary

This is a multicenter, 18-month study, which aims to identify imaging and biofluid biomarkers in people with ALS to expand the understanding of ALS pathology, treatment targets, disease progression, and anatomical differences between different disease phenotypes. This pilot project is tailored to produce imaging tools that will allow researchers to conduct future ALS clinical trials more efficiently which may in turn impact the pace for ALS drug discovery.

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG

[18F] GE-180

PET Tracer Ligand

Sponsors & Collaborators

  • The Methodist Hospital Research Institute

    collaborator OTHER

  • Cedars-Sinai Medical Center

    collaborator OTHER

  • ALS Association

    collaborator OTHER

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Suma Babu, MD · Massachusetts General Hospital

  • Joseph Masdeu, MD, PhD · Houston Methodist Neurological Institute

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2019-06-28
Completion
2019-06-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02559869 on ClinicalTrials.gov